TOKYO and HENNIGSDORF, Germany, Oct. 3, 2022 /PRNewswire/ — Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pantherna Therapeutics GmbH (CEO:Klaus Giese, Ph.D., “Pantherna”) as we speak introduced that the businesses have entered into a brand new expertise analysis settlement for analysis to generate mRNA-based regenerative drugs applications utilizing direct reprogramming (transdifferentiation)*.
This settlement expands the scope of the expertise analysis settlement for analysis, which Astellas and Pantherna entered into in 2021, to incorporate new goal organ.
Pantherna owns a proprietary platform of state-of-the-art, distinctive mRNA molecules (PTXmRNAs) for enhancing the effectivity of mRNA actions within the physique. Underneath the brand new settlement, Pantherna’s mRNA platform and Astellas’ world-class drug discovery capabilities will probably be mixed to advertise analysis on the technology of regenerative drugs applications for brand new goal organ utilizing a direct reprogramming strategy. Astellas will probably be liable for offering drug discovery concepts, making ready candidate compounds for expertise analysis, and performing analysis aimed toward growing this therapeutic modality, whereas Pantherna will probably be liable for offering technical data and growth help.
“We’re enthusiastic about this enlargement of our collaboration with Astellas,” stated Pantherna’s Chief Government Officer, Klaus Giese, Ph.D. “We really feel honored that Astellas, as a number one pharmaceutical firm, has underscored their curiosity in leveraging the distinctive facets of our proprietary therapeutic mRNA expertise.”
“By means of this settlement, which expands the scope of our collaboration with Pantherna, we are going to create modern regenerative drugs applications for brand new goal organ, and we anticipate that we can thereby broaden the remedy choices for illnesses with excessive unmet medical wants.” stated Taiji Sawamoto, Ph.D., Government Vice President, Utilized Analysis & Operations, at Astellas. “The collaboration with Pantherna is an initiative which synergistically integrates Astellas’ experience with mRNA as a therapeutic modality and its capabilities cultivated within the analysis area of direct reprogramming, and can promote the event of next-generation therapies utilizing a brand new modality/expertise primarily based on the Focus Space strategy technique.”
* Direct reprogramming: Direct conversion of the destiny of cells with out passing via the pluripotent state. https://www.astellas.com/en/science/direct-reprogramming-research-unit
Astellas Pharma Inc. is a pharmaceutical firm conducting enterprise in additional than 70 nations world wide. We’re selling the Focus Space Strategy that’s designed to determine alternatives for the continual creation of recent medicine to handle illnesses with excessive unmet medical wants by specializing in Biology and Modality. Moreover, we’re additionally trying past our foundational Rx focus to create Rx+® healthcare options that mix our experience and data with cutting-edge expertise in several fields of exterior companions. By means of these efforts, Astellas stands on the forefront of healthcare change to show modern science into worth for sufferers. For extra data, please go to our web site at https://www.astellas.com/en.
Pantherna Therapeutics is a privately held biopharmaceutical firm growing first-in-class therapeutics for vascular illnesses. Pantherna’s modern expertise platform is predicated on superior lipid nanoparticles for the target-specific, selective supply and expression of therapeutic mRNA medicine in organs and tissues such because the endothelium. Pantherna Therapeutics was just lately awarded with a 2022 Pharma Development Honor for its lead candidate PAN004 within the class “Most Modern Product: Leap Improvements-Nucleic Acid-Primarily based Drug Improvement”
(https://businesswire.com/news/home/20220916005215/en/Pharma-Trend-Honors-the-Best-Pharmaceutical-Companies-and-the-Most-Innovative-Products_2022). Pantherna is predicated in Hennigsdorf, Brandenburg (Innovationsforum) near Berlin, Germany. For extra data, please go to our web site at https://pantherna-therapeutics.com/.
Cautionary Notes (Astellas)
On this press launch, statements made with respect to present plans, estimates, methods and beliefs and different statements that aren’t historic info are forward-looking statements in regards to the future efficiency of Astellas. These statements are primarily based on administration’s present assumptions and beliefs in gentle of the knowledge presently obtainable to it and contain identified and unknown dangers and uncertainties. Quite a few components might trigger precise outcomes to vary materially from these mentioned within the forward-looking statements. Such components embody, however will not be restricted to: (i) adjustments typically financial situations and in legal guidelines and rules, referring to pharmaceutical markets, (ii) forex change price fluctuations, (iii) delays in new product launches, (iv) the shortcoming of Astellas to market current and new merchandise successfully, (v) the shortcoming of Astellas to proceed to successfully analysis and develop merchandise accepted by clients in extremely aggressive markets, and (vi) infringements of Astellas’ mental property rights by third events.
Details about pharmaceutical merchandise (together with merchandise presently in growth) which is included on this press launch is just not meant to represent an commercial or medical recommendation.
SOURCE Astellas Pharma Inc.